TN-201
MYBPC3-associated Hypertrophic Cardiomyopathy (HCM)
Key Facts
Indication
MYBPC3-associated Hypertrophic Cardiomyopathy (HCM)
Phase
Phase 1b/2
Status
Active
Company
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotech dedicated to discovering and delivering curative therapies for the underlying genetic drivers of heart disease. The company has reported promising early clinical data for its two lead gene therapy programs, TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC, and is advancing a preclinical small molecule, TN-301, for Duchenne muscular dystrophy. Its strategy leverages a precision medicine approach, validated genetic targets, and a multi-modal platform to address significant unmet needs in cardiovascular and neuromuscular diseases.
View full company profile